A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: Results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML) Meeting Abstract

  


Authors: Dawson, M.; Stein, E. M.; Huntly, B. J. P.; Karadimitris, A.; Kamdar, M.; de Larrea, C. F.; Dickinson, M. J.; Yeh, P. S. H.; Daver, N.; Chaidos, A.; Tallman, M. S.; Jiménez, R.; Horner, T.; Baron, J.; Brennan, J.; Ferron-Brady, G.; Wu, Y.; Karpinich, N.; Kremer, B.; Dhar, A.; Borthakur, G.
Abstract Title: A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: Results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML)
Meeting Title: 59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 130
Issue: Suppl. 1
Meeting Dates: 2017 Dec 9-12
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-12-07
Language: English
ACCESSION: WOS:000432419403201
PROVIDER: wos
DOI: 10.1182/blood.V130.Suppl_1.1377.1377
Notes: Meeting Abstract: 1377 -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Eytan Moshe Stein
    364 Stein
  2. Martin Stuart Tallman
    653 Tallman
Related MSK Work